Are PEGylated liposomes better than conventional liposomes? A special case for vincristine

Drug Delivery

Volumn 23, Issue 4, 2016, Pages 1092-1100

  Wang, Xuling ^a   Song, Yanzhi ^a   Su, Yuqing ^a   Tian, Qingjing ^a   Li, Boqun ^a   Quan, Jingjing ^a   Deng, Yihui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Leakage; liposomes; PEGylation; sphingomyelin; vincristine

Indexed keywords

CHOLESTEROL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LIPOSOME; PREDNISONE; RITUXIMAB; SPHINGOMYELIN; VINCRISTINE; ANTINEOPLASTIC AGENT; DRUG CARRIER; MACROGOL DERIVATIVE;

ABDOMINAL CRAMP; ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CIRCULATION TIME; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; FEVER; FOOD AND DRUG ADMINISTRATION; HAIR LOSS; HUMAN; MEMBRANE PERMEABILITY; MONOTHERAPY; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SENSORY NEUROPATHY; THROMBOCYTOPENIA; UNITED STATES; VOMITING; CHEMISTRY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHOLESTEROL; DRUG CARRIERS; HUMANS; LIPOSOMES; POLYETHYLENE GLYCOLS; SPHINGOMYELINS; UNITED STATES; VINCRISTINE;

EID: 84975322664     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2015.1027015     Document Type: Review

References (67)

1. A.Albanese, P.S.Tang, W.C.Chan. (2012). The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–16
2. T.M.Allen, M.S.Newman, M.C.Woodle,. (1995). Pharmacokinetics and anti-tumor activity of vincristine encapsulated in sterically stabilized liposomes. Int J Cancer 62:199–204
3. D.Aminoff, W.F.Bruegge, W.C.Bell,. (1977). Role of sialic acid in survival of erythrocytes in the circulation: interaction of neuraminidase-treated and untreated erythrocytes with spleen and liver at the cellular level. Proc Natl Acad Sci USA 74:1521–4
4. B.C.Baguley, K.M.Holdaway, L.L.Thomsen,. (1991). Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 27:482–7
5. S.Bandak, D.Goren, A.Horowitz,. (1999). Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models. Anticancer Drugs 10:911–20
6. Y.Barenholz. (2012). Doxil®--the first FDA-approved nano-drug: lessons learned. J Control Release 160:117–34
7. A.Y.Bedikian, N.E.Papadopoulos, K.B.Kim,. (2008). A pilot study with vincristine sulfate liposome infusion in patients with metastatic melanoma. Melanoma Res 18:400–4
8. A.Y.Bedikian, T.Sato, K.B.Kim,. (2009). Phase II study of vincristine sulfate liposomes injection in patients with metastatic uveal melanoma. J Clin Oncol (2009 ASCO Annual Meeting) 27:15
9. N.L.Boman, D.Masin, L.D.Mayer,. (1994). Liposomal vincristine which exhibits increased drug retention and increased circulation longevity cures mice bearing P388 tumors. Cancer Res 54:2830–3
10. N.L.Boman, L.D.Mayer, P.R.Cullis. (1993). Optimization of the retention properties of vincristine in liposomal systems. Biochim Biophys Acta 1152:253–8
11. D.Bratosin, J.Mazurier, J.P.Tissier,. (1998). Cellular and molecular mechanisms of senescent erythrocyte phagocytosis by macrophages: a review. Biochimie 80:173–95
12. P.P.Carbone, B.Vincent, E.FreiIII, C.O.Brindley. (1963). Clinical studies with vincristine. Blood 21:640–7
13. L.Cattel, M.Ceruti, F.Dosio. (2003). From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 89:237–49
14. D.D.Chow, H.E.Essien, M.M.Padki, K.J.Hwang. (1989). Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. J Pharmacol Exp Ther 248:506–13
15. J.L.Cui, C.Wang,. (2011). Development of pegylated liposomal vincristine using novel sulfobutyl ether cyclodextrin gradient: is improved drug retention sufficient to surpass DSPE-PEG-induced drug leakage? J Pharm Sci 100:2835–48
16. J.Damen, J.Regts, G.Scherphof. (1981). Transfer and exchange of phospholipid between small unilamellar liposomes and rat plasma high density lipoproteins. Dependence on cholesterol content and phospholipid composition. Biochim Biophys Acta 665:538–45
17. E.T.Dams, P.Laverman, W.J.Oyen,. (2000). Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. J Pharmacol Exp Ther 292:1071–9
18. L.Embree, K.Gelmon, A.Tolcher,. (1997). Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. Cancer Chemother Pharmacol 41:347–52
19. K.A.Gelmon, A.Tolcher, A.R.Diab,. (1999). Phase I study of liposomal vincristine. J Clin Oncol 17:697–705
20. R.Hennig, K.Pollinger, A.Veser,. (2014). Nanoparticle multivalency counterbalances the ligand affinity loss upon PEGylation. J Control Release 194:20–7
21. R.H.Himes. (1991). Interactions of the catharanthus (Vinca) alkaloids with tubulin and microtubules. Pharmacol Ther 51:257–67
22. Y.T.Hitoshi, K.Takashi,. (1995). Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes. Int J Pharm 113:141–8
23. G.M.Jensen, T.Bunch. (2007). Conventional liposome performance and evaluation: lessons from the development of Vescan. J Liposome Res 17:121–37
24. I.S.Johnson, J.Armstrong, M.Gorman, J.P.BurnettJr. (1963). The vinca alkaloids: a new class of oncolytic agents. Cancer Res 23:1390–427
25. M.J.Johnston, S.C.Semple, S.K.Klimuk,. (2006). Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 1758:55–64
26. M.J.Johnston, S.C.Semple, S.K.Klimuk,. (2007). Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochim Biophys Acta 1768:1121–7
27. M.A.Jordan, D.Thrower, L.Wilson. (1991). Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res 51:2212–22
28. L.D.Kaplan, S.Deitcher, J.A.Silverman, G.Morgan. (2014). Phase II study of vincristine sulfate liposome injection (Marqibo) and rituximab for patients with relapsed and refractory diffuse large B-Cell lymphoma or mantle cell lymphoma in need of palliative therapy. Clin Lymphoma Myeloma Leuk 14:37–42
29. C.Kirby, G.Gregoriadis. (1983). The effect of lipid composition of small unilamellar liposomes containing melphalan and vincristine on drug clearance after injection into mice. Biochem Pharmacol 32:609–15
30. R.Krishna, M.Webb, O.StOnge, L.D.Mayer. (2001). Liposomal and non-liposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther 298:1206–12
31. P.Laverman, M.Carstens, O.C.Boerman,. (2001). Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. J Pharmacol Exp Ther 298:607–12
32. D.Layton, A.Trouet. (1980). A comparison of the therapeutic effects of free and liposomally encapsulated vincristine in leukemic mice. Eur J Cancer 16:945–50
33. J.H.Lee, A.Nan. (2012). Combination drug delivery approaches in metastatic breast cancer. Drug Deliv, Early Online: 1-17. doi: http://dx.doi.org/10.1155/2012/915375
34. A.Leo, C.Hansch, D.Elkins. (1971). Partition coefficients and their uses. Chem Rev 71:525–616
35. H.Maeda, J.Wu, T.Sawa,. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271–84
36. L.D.Mayer, M.Bally, H.Loughrey,. (1990). Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res 50:575–9
37. Y.Namba, T.Sakakibara, M.Masada,. (1990). Glucuronate-modified liposomes with prolonged circulation time. Chem Pharm Bull 38:1663–6
38. R.L.Nelson, R.W.Dyke, M.A.Root. (1977). Comparative pharmacokinetics of the vinca alkaloids in man. Clin Pharmacol Ther 21:112
39. T.Nishiya, R.Lam, F.Eng,. (1995). Mechanistic study on toxicity of positively charged liposomes containing stearylamine to blood. Artif Cells Blood Substit Immobil Biotechnol 23:505–12
40. C.O.Noble, Z.Guo, M.E.Hayes,. (2009). Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine. Cancer Chemother Pharmacol 64:741–51
41. R.L.Noble. (1990). The discovery of the vinca alkaloids-chemotherapeutic agents against cancer. Biochem Cell Biol 68:1344–51
42. S.O'brien, G.Schiller, J.Lister,. (2013). High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia. J Clin Oncol 31:676–83
43. N.N.Oku, S.Okada. (1992). Tumor accumulation of novel RES-avoiding liposomes. Biochim Biophys Acta 1126:255–60
44. D.E.Owens3rd, N.A.Peppas. (1996). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307:93–102
45. M.A.Rodriguez, R.Pytlik, T.Kozak,. (2009). Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study. Cancer 115:3475–82
46. Rodriguez, A.Maria, L.Fayad,. (2005). Phase II study of sphingosomal vincristine in CHOP+/− rixtuximab for patients with aggressive non-Hodgkin's lymphoma (NHL): promising 3 year follow-up results in elderly patients. Blood (ASH Annual Meeting Abstracts) 106:943
47. E.K.Rowinsky, R.C.Donehower. (1991). The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther 52:35–84
48. A.H.Sarris, F.Hagemeister, J.Romaguera,. (2000). Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol 11:69–72
49. C.F.B.Schmidt, T.E.Thompson. (1977). A nuclear magnetic resonance study of sphingomyelin in bilayer systems. Biochemistry 16:2649–56
50. V.S.Sethi, D.V.JacksonJr, D.R.White,. (1981). Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Res 41:3551–5
51. E.J.Shimshick, H.McConnell. (1973). Lateral phase separation in phospholipid membranes. Biochemistry 12:2351–60
52. G.H.Svoboda, I.JohnsonIs, M.Gorman, N.Neuss. (1962). Current status of research on the alkaloids of Vinca rosea Linn. (Catharanthus roseus G. Don). J Pharm Sci 51:707–20
53. H.P.Thakkar, A.Baser, M.P.Parmar,. (2012). Vincristine-sulphate-loaded liposome-templated calcium phosphate nanoshell as potential tumor-targeting delivery system. J Liposome Res 22:139–47
54. D.A.Thomas, H.Kantarjian, W.Stock,. (2009). Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia. Cancer 115:5490–8
55. D.A.Thomas, A.Sarris, J.Cortes,. (2006). Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106:120–7
56. Y.Tokudome, N.Oku, K.Doi,. (1996). Antitumor activity of vincristine encapsulated in glucuronide-modified long-circulating liposomes in mice bearing Meth A sarcoma. Biochim Biophys Acta 1279:70–4
57. A.Urruticoechea, R.Alemany, J.Balart,. (2010). Recent advances in cancer therapy: an overview. Curr Pharm Des 16:3–10
58. J.Vaage, D.Donovan, E.Mayhew,. (1993). Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilized liposomes. Int J Cancer 54:959–64
59. F.M.Veronese, G.Pasut. (2005). PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451–8
60. M.S.Webb, T.Harasym, D.Masin,. (1995). Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer 72:896–904
61. M.S.Webb, D.Saxon, F.M.Wong,. (1998). Comparison of different hydrophobic anchors conjugated to poly(ethylene glycol): effects on the pharmacokinetics of liposomal vincristine. Biochim Biophys Acta 1372:272–82
62. Xu H, Ye F, Hu M, et al. (2014). Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Deliv, Early Online: 1-10. doi: http://dx.doi.org/10.3109/10717544.2014.885998
63. M.Yamauchi, K.Tsutsumi, M.Abe,. (2007). Release of drugs from liposomes varies with particle size. Biol Pharm Bull 30:963–6
64. W.C.Zamboni, A.Gervais, M.J.Egorin,. (2004). Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol 53:329–36
65. L.Zhang, H.Gao, L.Chen,. (2008). Tumor targeting of vincristine by mBAFF-modified PEG liposomes in B lymphoma cells. Cancer Lett 269:26–36
66. I.V.Zhigaltsev, N.Maurer, Q.F.Akhong,. (2005). Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention. J Control Release 104:103–11
67. G.Zhu, E.Oto, J.Vaage,. (1996). The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity. Cancer Chemother Pharmacol 39:138–42